Where are we now? An update on Parkinson's Disease drugs, clinical trials, wearable apps and research in 2016. Nuplazid Pimavanserin Approval & Cost Nuplazid was approved by the F.D.A. on April 29, 2016 after being fastracked through the approval process via the priority review status at the FDA. The priority review status is granted to promising drugs and speeds up the drug review process. Noteworthy is the current Phase II clinical trial of Nuplazid and Alzheimer's Disease … [Read more...] about Parkinson’s Disease: The Year In Review 2016
Nuplazid Parkinson's
Nuplazid Update For Parkinson’s Drug
Nuplazid, a promising yet unapproved drug for Parkinson's disease has been granted Priority Review status by the Federal Food & Drug Administration (FDA) in November 2015. The FDA's Priority Review designation is significant as a decision by the FDA will now be granted by May 1, 2016; priority review designation fast tracks a drug's approval process through the FDA for drugs. Nuplazid And Parkinson's PDP If approved, Nuplazid would be the first FDA approved drug to treat … [Read more...] about Nuplazid Update For Parkinson’s Drug